In this exciting extended Q&A; session, Dr. James Knoll addresses your unanswered questions from his presentation on Mass Shootings.

E87 - NEI Max! 2020 Extended Q&A  with Dr. James Knoll

The Neuroscience Education Institute (NEI) is committed to help raise the standard of mental health by providing imaginative medical education that focuses on the highest level of learning. Each episode offers an opportunity to learn about current issues in psychiatry from key opinion leaders in the medical field. NEI's Podcast would be of value to anyone with an interest in neuropsychiatric diseases and psychopharmacology.

Education

Training

Language Courses

Higher Education

K-12

Educational Technology

Medicine

Science & Medicine

Health & Fitness

How do symptoms of agitation manifest differently in disorders such as bipolar disorder, schizophrenia, and dementia, and what challenges does this pose for assessment? What are the most effective pharmacological treatments for acute agitation in psychiatric patients, and how do you determine the best course of action? How do cultural factors influence the approach to managing agitation in various mental health conditions?  Brought to you by the NEI Podcast, the PsychopharmaStahlogy Show tackles the most novel, exciting, and controversial topics in psychopharmacology in a series of themes. This theme is on the “untreatable” dimensions of psychopathology.  Today, Dr. Andy Cutler interviews Dr. Leslie Citrome and Dr. Stephen Stahl about the clinical difficulties of treating agitation.   Let’s listen to Part 3 of our theme: Untreatable Dimensions of Psychopathology.   Subscribe to the NEI Podcast, so that you don’t miss another episode!

E225 - The PsychopharmaStahlogy Show: Untreatable Dimensions of Psychopathology: Agitation with Dr. Leslie Citrome

 What are the hypothesized neurobiological mechanisms that support the use of cannabidiol (CBD) as a treatment for opioid use disorder (OUD)? How does CBD influence cue-induced craving in OUD? What are the challenges and opportunities in further exploring the use of CBD as a potential treatment for OUD?  Dr. Joji Suzuki is the Director of the Division of Addiction Psychiatry and Director of Addictions Education in the Department of Psychiatry, Brigham and Women’s Hospital, and an Assistant Professor of Psychiatry at Harvard Medical School. His areas of clinical and research interests are the assessment and management of substance use disorders and related conditions in general medical settings, motivational interviewing, office-based opioid treatment, implementation of collaborative models of care, and medical education. He is the site director for the Partners Addiction Psychiatry Fellowship, and is involved with teaching medical students, residents, and allied health professionals. He has authored over 30 peer-reviewed manuscripts and book chapters related to addiction psychiatry.

E224 - Is Cannabidiol Useful for the Treatment of Opioid Use Disorder? with Dr. Joji Suzuki

 In this episode, Dr. David Goodman addresses your unanswered questions from his presentation, Setting the Mood: Strategies for Diagnosing and Treating ADHD in the Context of Bipolar Disorder, delivered at 2024 NEI Synapse in Las Vegas, Nevada.

E223 - 2024 NEI Synapse Extended Q&A: Diagnosing and Treating Comorbid ADHD and Bipolar Disorder with Dr. David Goodman

 In this episode, Dr. Manpreet Singh addresses your unanswered questions from her joint presentation, Don’t Get Mixed Up! Recognizing and Treating Mixed Features Across the Lifespan, delivered at 2024 NEI Synapse in Las Vegas, Nevada.

E222 - 2024 NEI Synapse Extended Q&A: Recognizing and Treating Mixed Features Across the Lifespan with Dr. Manpreet Singh

 In this episode, Dr. Dani Cabral addresses your unanswered questions from her presentation, Memories in the Future: An Update on the Diagnosis and Treatment of Alzheimer’s Disease, delivered at 2024 NEI Synapse in Las Vegas, Nevada.

E87 - NEI Max! 2020 Extended Q&A with Dr. James Knoll

Download our free app to listen on your phone